Roivant Sciences (ROIV) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Jul, 2026Executive summary
Annual General Meeting scheduled for September 16, 2026, in London, with voting available online or in person.
Shareholders are encouraged to review proxy materials and vote by September 15, 2026.
Voting matters and shareholder proposals
Election of two nominees, Daniel Gold and Meghan FitzGerald, as Class II Directors for a three-year term.
Ratification of Ernst & Young LLP as independent auditor for the fiscal year ending March 31, 2027, including statutory appointment and remuneration authorization.
Advisory, non-binding vote on executive compensation for named executive officers.
Proxies may vote on other business as may properly come before the meeting.
Board of directors and corporate governance
Board recommends voting in favor of all director nominees and proposals.
Latest events from Roivant Sciences
- $950M Moderna payment, $3.9B cash, and key product launch set up a catalyst-rich 2026.ROIV
Q1 2027 - Proxy covers director elections, auditor ratification, say-on-pay, and highlights governance and ESG.ROIV
Proxy filing - Graves' disease and dermatomyositis lead strategic focus, with key data and commercialization ahead.ROIV
TD Cowen 45th Annual Healthcare Conference - Brepocitinib leads a robust pipeline targeting rare diseases, with strong data and launch plans.ROIV
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Late-stage pipeline advances and imminent DM launch set up multiple catalysts for the year.ROIV
Jefferies Global Healthcare Conference 2026 - Strong Phase II efficacy for brepocitinib and $4.5B cash position support future catalysts.ROIV
Q3 2026 - Strong clinical progress, $4.4B cash, and multiple late-stage milestones expected through 2028.ROIV
Q2 2026 - Largest DM trial tests oral dual TYK2/JAK1 inhibitor with pivotal data expected in 2025.ROIV
Status Update - Strong clinical progress, major asset sale, and $5.4B cash with no debt highlight the quarter.ROIV
Q2 2025